Somewhat Favorable Media Coverage Somewhat Unlikely to Impact ImmunoGen (IMGN) Stock Price
News coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.5088883358682 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- ImmunoGen, Inc. (IMGN) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Outline of Different Gauges: ImmunoGen, Inc. (IMGN), MGIC Investment Corporation (MTG) – Market Movers (financialqz.com)
- ImmunoGen (IMGN) Soars: Stock Adds 10.3% in Session – Nasdaq (nasdaq.com)
- ImmunoGen (IMGN) to Release Quarterly Earnings on Friday (americanbankingnews.com)
- Here’s What’s Lifting ImmunoGen, Inc. Shares Today – Motley Fool (fool.com)
Shares of ImmunoGen (NASDAQ:IMGN) opened at $9.76 on Monday. The company has a current ratio of 2.81, a quick ratio of 2.78 and a debt-to-equity ratio of -0.03. The stock has a market capitalization of $1,290.76, a PE ratio of -7.51 and a beta of 2.50. ImmunoGen has a 52-week low of $2.28 and a 52-week high of $10.04.
IMGN has been the subject of a number of recent analyst reports. Zacks Investment Research raised ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research report on Tuesday, October 31st. Jefferies Group reissued a “buy” rating and set a $9.00 price objective on shares of ImmunoGen in a research report on Thursday, October 12th. Cantor Fitzgerald reissued a “hold” rating and set a $5.00 price objective on shares of ImmunoGen in a research report on Friday, November 3rd. BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, January 18th. Finally, HC Wainwright initiated coverage on ImmunoGen in a research report on Wednesday, January 31st. They set a “buy” rating for the company. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. ImmunoGen currently has an average rating of “Buy” and an average price target of $7.83.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.